Nothing Special   »   [go: up one dir, main page]

NO20063330L - Amidderivater med en syklopropylaminokarbonylsubstituent som er nyttige som cytokininhibitorer - Google Patents

Amidderivater med en syklopropylaminokarbonylsubstituent som er nyttige som cytokininhibitorer

Info

Publication number
NO20063330L
NO20063330L NO20063330A NO20063330A NO20063330L NO 20063330 L NO20063330 L NO 20063330L NO 20063330 A NO20063330 A NO 20063330A NO 20063330 A NO20063330 A NO 20063330A NO 20063330 L NO20063330 L NO 20063330L
Authority
NO
Norway
Prior art keywords
cyclopropylaminocarbonyl
amide derivatives
cytokine inhibitors
compounds
substituent useful
Prior art date
Application number
NO20063330A
Other languages
English (en)
Other versions
NO337886B1 (no
Inventor
Dearg Sutherland Brown
John Graham Cumming
Ian Alun Nash
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30776197&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20063330(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of NO20063330L publication Critical patent/NO20063330L/no
Publication of NO337886B1 publication Critical patent/NO337886B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

Oppfinnelsen beskriver en forbindelse med Formel (I) der Qa er heteroaryl og er substituert med halogen; R1 og R2 er hver hydrogen; og Qb er fenyl eller heteroaryl, og Qb eventuelt kan bære 1 eller 2 substituenter valgt blant hydroksy, halogen og (C1-6)alkyl, eller et farmasøytisk akseptabelt salt derav. Det beskrives videre fremgangsmåter for fremstilling av disse forbindelser, farmasøytiske preparater inneholdende forbindelsene og forbindelsenes og preparatenes anvendelse ved behandling av sykdommer eller medisinske tilstander som medieres av cytokiner.
NO20063330A 2003-12-20 2006-07-18 Amidderivater med en syklopropylaminokarbonylsubstituent, fremgangsmåte for fremstilling derav, farmasøytisk preparat inneholdende slike, og anvendelse derav ved behandling av artritt. NO337886B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0329572.2A GB0329572D0 (en) 2003-12-20 2003-12-20 Amide derivatives
PCT/GB2004/005241 WO2005061465A1 (en) 2003-12-20 2004-12-15 Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cyto kine inhibitors

Publications (2)

Publication Number Publication Date
NO20063330L true NO20063330L (no) 2006-09-14
NO337886B1 NO337886B1 (no) 2016-07-04

Family

ID=30776197

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063330A NO337886B1 (no) 2003-12-20 2006-07-18 Amidderivater med en syklopropylaminokarbonylsubstituent, fremgangsmåte for fremstilling derav, farmasøytisk preparat inneholdende slike, og anvendelse derav ved behandling av artritt.

Country Status (34)

Country Link
US (3) US7943776B2 (no)
EP (1) EP1699766B1 (no)
JP (1) JP5046650B2 (no)
KR (1) KR101151530B1 (no)
CN (1) CN1918134B (no)
AR (1) AR046968A1 (no)
AT (1) ATE477246T1 (no)
AU (1) AU2004303579B8 (no)
BR (1) BRPI0417844A (no)
CA (1) CA2547617C (no)
CY (1) CY1111980T1 (no)
DE (1) DE602004028656D1 (no)
DK (1) DK1699766T3 (no)
ES (1) ES2350226T3 (no)
GB (1) GB0329572D0 (no)
HK (1) HK1092797A1 (no)
HR (1) HRP20100592T1 (no)
IL (1) IL175998A0 (no)
ME (1) ME01851B (no)
MX (1) MXPA06006660A (no)
MY (1) MY145908A (no)
NO (1) NO337886B1 (no)
NZ (1) NZ547998A (no)
PL (1) PL1699766T3 (no)
PT (1) PT1699766E (no)
RS (1) RS51417B (no)
RU (1) RU2382028C2 (no)
SA (1) SA04250419B1 (no)
SI (1) SI1699766T1 (no)
TW (1) TWI342214B (no)
UA (1) UA88777C2 (no)
UY (1) UY28688A1 (no)
WO (1) WO2005061465A1 (no)
ZA (1) ZA200604973B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308201D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
ES2386784T3 (es) 2003-05-01 2012-08-30 Bristol-Myers Squibb Company Compuestos de pirazol-amina útiles como inhibidores de quinasas
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
JP2010508288A (ja) * 2006-10-27 2010-03-18 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なヘテロサイクリックアミド化合物
US20090281150A1 (en) * 2008-04-09 2009-11-12 Nicola Frances Bateman Compound 249
WO2009138778A1 (en) * 2008-05-12 2009-11-19 Astrazeneca Ab Cyclopropyl benzamide derivatives as intermediates for cytokine inhibitors
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
WO2011010132A1 (en) 2009-07-21 2011-01-27 Astrazeneca Ab Sustained-release composition comprising compound 600
WO2016001452A1 (en) * 2014-07-04 2016-01-07 Universität Zürich Compounds, in particular for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated
CN110352189A (zh) * 2017-02-24 2019-10-18 景凯生物科技股份有限公司 用于预防及/或治疗自体免疫、发炎或感染相关障碍的磺酰胺或酰胺化合物、组合物与方法
WO2024039864A1 (en) * 2022-08-19 2024-02-22 Purdue Research Foundation Protein:protein interaction inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
GB9816837D0 (en) * 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
EP1062210B1 (en) * 1998-03-09 2005-06-01 Vertex Pharmaceuticals Incorporated 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
GB2336362A (en) * 1998-04-17 1999-10-20 Xenova Ltd Cytokine production inhibitors
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
US7169771B2 (en) 2003-02-06 2007-01-30 Bristol-Myers Squibb Company Thiazolyl-based compounds useful as kinase inhibitors
US7263483B2 (en) 2003-04-28 2007-08-28 Dictaphone Corporation USB dictation device
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives

Also Published As

Publication number Publication date
CA2547617A1 (en) 2005-07-07
HK1092797A1 (en) 2007-02-16
RS51417B (en) 2011-02-28
AU2004303579B8 (en) 2008-05-01
SI1699766T1 (sl) 2010-12-31
ES2350226T3 (es) 2011-01-20
MXPA06006660A (es) 2006-08-11
US20070135440A1 (en) 2007-06-14
NO337886B1 (no) 2016-07-04
KR101151530B1 (ko) 2012-07-05
AU2004303579B2 (en) 2008-04-03
CN1918134B (zh) 2010-11-10
TW200524620A (en) 2005-08-01
MY145908A (en) 2012-05-15
ATE477246T1 (de) 2010-08-15
NZ547998A (en) 2009-03-31
AU2004303579A1 (en) 2005-07-07
DE602004028656D1 (en) 2010-09-23
JP2007516979A (ja) 2007-06-28
IL175998A0 (en) 2006-10-05
US8742124B2 (en) 2014-06-03
US20130035346A1 (en) 2013-02-07
EP1699766B1 (en) 2010-08-11
US20120004243A1 (en) 2012-01-05
KR20060123352A (ko) 2006-12-01
DK1699766T3 (da) 2010-11-01
SA04250419B1 (ar) 2009-01-19
CA2547617C (en) 2013-02-05
UA88777C2 (en) 2009-11-25
PL1699766T3 (pl) 2011-01-31
GB0329572D0 (en) 2004-01-28
HRP20100592T1 (hr) 2010-12-31
BRPI0417844A (pt) 2007-04-17
ME01851B (me) 2011-02-28
UY28688A1 (es) 2005-07-29
AR046968A1 (es) 2006-01-04
EP1699766A1 (en) 2006-09-13
TWI342214B (en) 2011-05-21
RU2006125634A (ru) 2008-01-27
US7943776B2 (en) 2011-05-17
PT1699766E (pt) 2010-10-11
CN1918134A (zh) 2007-02-21
CY1111980T1 (el) 2015-11-04
WO2005061465A1 (en) 2005-07-07
RU2382028C2 (ru) 2010-02-20
ZA200604973B (en) 2007-05-30
JP5046650B2 (ja) 2012-10-10

Similar Documents

Publication Publication Date Title
NO20063330L (no) Amidderivater med en syklopropylaminokarbonylsubstituent som er nyttige som cytokininhibitorer
RU2403251C2 (ru) Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70
NO20064297L (no) Aminoalkoholforbindelse
NO20063549L (no) (3-okso-3,4-dihydro-quinoksalin-2-yl-amino)-Benzamidderivater og relatert forbindelse som glykogenfosforylaseinhibitorer for behandling av diabetes og fedme
ATE454152T1 (de) 2-aminopyrimidin-derivate als raf-kinase-hemmer
NO20051051L (no) Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme i terapeutiske midler
NO20062370L (no) Amidderivater
NO20074763L (no) (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi
NO20091858L (no) Hydrobenzamid derivater som inhibitorer av HSP90
NO20050828L (no) lndol-3-svovelderivater
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
RU2003122190A (ru) Производные тетрагидропиридина, их получение и применение в качестве ингибиторов клеточной пролиферации
NO20075169L (no) Nye imidazo (1,5-A)pyndindenvater, fremgangsmate for fremstilling og farmasoytiske sammensetninger som inneholder samme.
NO20072053L (no) Nye bis-azaindolderivater, fremstilling og farmasoytisk anvendelse derav som kinaseinhibitorer
DE602005022764D1 (de) Piperidin- und azetidinderivate als glyt1-inhibitoren
NO20082077L (no) Spirosykliske quinazolinderivater som PDE7-inhibitorer
ATE535241T1 (de) Verwendung von 3-(indolyl)- oder 3-(azaindolyl)-4-arylmaleimid-derivaten bei der behandlung von leukämie
SE0201937D0 (sv) Therapeutic agents
JP2005538111A5 (no)
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы
DE602004020730D1 (de) Pharmazeutisches verfahren und damit hergestellte verbindungen
EA200500095A1 (ru) Производные 4-(7-гало-2-хино(кса-)линилокси)феноксипропионовой кислоты в качестве противоопухолевых средств
NO20082226L (no) 6-heteroarylpyridoindolonderivater, deres fremstilling og terapeutisk anvendelse derav
RU2008129623A (ru) Ингибиторы ccr9 активности
NO20061604L (no) Piperazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees